Fennec Pharmaceuticals Stock Return On Asset
| FENC Stock | USD 5.66 0.34 6.39% |
Fennec Pharmaceuticals fundamentals help investors to digest information that contributes to Fennec Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Fennec Stock. The fundamental analysis module provides a way to measure Fennec Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fennec Pharmaceuticals stock.
As of November 26, 2024, Return On Assets is expected to decline to -0.63. Fennec | Return On Asset |
Fennec Pharmaceuticals Company Return On Asset Analysis
Fennec Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Fennec Pharmaceuticals Return On Asset | 0.027 |
Most of Fennec Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fennec Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Fennec Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Fennec Pharmaceuticals is extremely important. It helps to project a fair market value of Fennec Stock properly, considering its historical fundamentals such as Return On Asset. Since Fennec Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fennec Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fennec Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Fennec Total Assets
Total Assets |
|
Based on the latest financial disclosure, Fennec Pharmaceuticals has a Return On Asset of 0.027. This is 100.31% lower than that of the Biotechnology sector and 100.11% lower than that of the Health Care industry. The return on asset for all United States stocks is 119.29% lower than that of the firm.
Fennec Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fennec Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fennec Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fennec Pharmaceuticals by comparing valuation metrics of similar companies.Fennec Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Fennec Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fennec Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fennec Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Fennec Fundamentals
| Return On Equity | -10.06 | ||||
| Return On Asset | 0.027 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.75) % | ||||
| Current Valuation | 146.91 M | ||||
| Shares Outstanding | 27.43 M | ||||
| Shares Owned By Insiders | 16.22 % | ||||
| Shares Owned By Institutions | 54.73 % | ||||
| Number Of Shares Shorted | 1.78 M | ||||
| Price To Earning | (3.82) X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 3.15 X | ||||
| Revenue | 21.25 M | ||||
| Gross Profit | 1.45 M | ||||
| EBITDA | (12.36 M) | ||||
| Net Income | (16.05 M) | ||||
| Cash And Equivalents | 14.91 M | ||||
| Cash Per Share | 0.57 X | ||||
| Total Debt | 30.95 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 5.12 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | (17.14 M) | ||||
| Short Ratio | 23.60 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 13.6 | ||||
| Number Of Employees | 29 | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 155.27 M | ||||
| Total Asset | 26.86 M | ||||
| Retained Earnings | (219.25 M) | ||||
| Working Capital | 19.3 M | ||||
| Current Asset | 7.88 M | ||||
| Current Liabilities | 1.97 M | ||||
| Net Asset | 26.86 M |
About Fennec Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fennec Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fennec Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fennec Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:Check out Fennec Pharmaceuticals Piotroski F Score and Fennec Pharmaceuticals Altman Z Score analysis. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 1.814 | Quarterly Revenue Growth 0.07 | Return On Assets 0.027 | Return On Equity (10.06) |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.